financetom
Business
financetom
/
Business
/
Japanese foreign equity purchases in April hit 20-year high on global market volatility
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Japanese foreign equity purchases in April hit 20-year high on global market volatility
May 26, 2025 5:37 AM

(Reuters) -Japanese investors sharply ramped up their overseas equity purchases in April, shifting away from bonds as they rebalanced portfolios amid global market volatility triggered by U.S. tariffs, and capitalizing on discounted international shares.

Japanese investors bought a net 3.27 trillion yen ($22.37 billion) in overseas stocks - the highest monthly total since at least 2005 - while pulling 1.08 trillion yen from foreign bonds, according to Ministry of Finance data released on Monday.

Institutional investors pulled 1.99 trillion yen from long-term debt securities but allocated a net 906.3 billion yen into short-term instruments. Trust accounts led equity purchases with a record 2.76 trillion yen, followed by investment trust firms, which added 801.4 billion yen in foreign stocks.

Life insurers, however, offloaded 462 billion yen in foreign shares, marking a fourth consecutive month of net selling.

U.S. Treasury yields rose in early April as bonds sold off, with hedge funds unwinding leveraged basis trades and overseas investors selling U.S. debt in apparent retaliation for tariffs, amid growing doubts about the safe-haven status of U.S. assets.

Separately, data released by the Bank of Japan on Monday showed Japanese investors pumped 2.12 trillion yen into U.S. equities in March - the most since at least 2014 - while trimming holdings of European stocks by a modest 21.82 billion yen.

Meanwhile, overseas investors snapped up 3.68 trillion yen in Japanese markets in April, the largest monthly inflow in two years.

Analysts suggested that early April buying was likely fuelled by optimism over Japanese companies, driven by corporate reforms, increased confidence in yen stability, and relatively attractive valuations compared with Western markets.

($1 = 146.1500 yen)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Donald Trump Set to Receive Windfall Payout if Trump Media & Technology Stock Remains Above $17.50
Donald Trump Set to Receive Windfall Payout if Trump Media & Technology Stock Remains Above $17.50
Apr 23, 2024
09:29 AM EDT, 04/23/2024 (MT Newswires) -- Trump Media & Technology Group's ( DJT ) majority owner Donald Trump is set for a windfall payout, assuming the stock doesn't lose more than half its value by the end of trading on Tuesday. According to Securities and Exchange Commission filings, Trump will receive an additional 36 million shares if the average...
NVR's Q1 Earnings, Revenue Rise
NVR's Q1 Earnings, Revenue Rise
Apr 23, 2024
09:26 AM EDT, 04/23/2024 (MT Newswires) -- NVR (NVR) reported Q1 earnings Tuesday of $116.41 per diluted share, up from $99.89 a year earlier. Analysts polled by Capital IQ expected $103.76. Revenue for the quarter ended March 31 was $2.29 billion, up from $2.13 billion a year earlier. Analysts surveyed by Capital IQ expected $2.25 billion. ...
US oil and gas M&A hits quarterly record after blockbuster 2023
US oil and gas M&A hits quarterly record after blockbuster 2023
Apr 23, 2024
* Diamondback's bid for Endeavor tops 1Q deal rankings * Top US shale field remains focus of energy M&A activity HOUSTON, April 23 (Reuters) - U.S. oil and gas deals hit a record $51 billion in the first quarter, a continuation of last year's fierce merger pace centered in the top U.S. shale field, data provider Enverus said on Tuesday....
ImmunityBio Gaining in Tuesday Pre-Market after FDA Approval for Anktiva-Bacterium Combination for Bladder Cancer
ImmunityBio Gaining in Tuesday Pre-Market after FDA Approval for Anktiva-Bacterium Combination for Bladder Cancer
Apr 23, 2024
09:27 AM EDT, 04/23/2024 (MT Newswires) -- ImmunityBio ( IBRX ) rose more than 23% in recent premarket activity on Tuesday after the US Food and Drug Administration approved a combination of the company's Anktiva immunotherapy and the Bacillus Calmette-Guerin bacterium in patients with a form of non-muscle invasive bladder cancer that previously was unresponsive to BGC therapy. The FDA...
Copyright 2023-2026 - www.financetom.com All Rights Reserved